Introduction
The route of administration significantly influences peptide bioavailability, stability, and research outcomes. Understanding the pharmacokinetic implications of each delivery method is essential for designing reproducible experimental protocols. See also our Peptide Reconstitution Guide and Peptide Storage & Stability guide for complementary preparation protocols.
For research and laboratory use only. Not intended for human or veterinary use.
Why Delivery Route Matters
Peptides are susceptible to enzymatic degradation in the gastrointestinal tract and rapid renal clearance in systemic circulation. The chosen delivery route directly affects:
- Absorption rate and peak plasma concentration (Cmax)
- Time to peak concentration (Tmax)
- Overall bioavailability (%F)
- Degradation profile and half-life
Subcutaneous Administration
- Bioavailability: Typically 75–100% for most research peptides, depending on molecular weight and formulation.
- Absorption: Slow, sustained release via lymphatic uptake — generally preferred for consistent plasma levels in research models.
- Common applications: BPC-157, TB-500, Semaglutide, CJC-1295 + Ipamorelin, IGF-1 LR3.
- Considerations: Injection site rotation recommended in longitudinal studies to avoid localised tissue changes. Reconstitute with bacteriostatic water for multi-dose vials.
Intraperitoneal Administration
- Bioavailability: High — rapid absorption via peritoneal vasculature.
- Absorption: Faster onset than subcutaneous; commonly used in rodent model research.
- Considerations: Not directly translatable to clinical delivery routes; used primarily in preclinical in vivo studies.
Intranasal Administration
- Bioavailability: Variable — typically lower than subcutaneous, but bypasses first-pass metabolism.
- Research interest: Growing focus on intranasal delivery for CNS-targeting peptides (e.g. Semax, Selank) due to direct olfactory-to-brain transport pathways. See our Nootropic & Cognitive Peptides overview for more on these compounds.
- Formulation requirements: Requires appropriate carrier solutions and pH adjustment for mucosal absorption.
Oral Administration
- Bioavailability: Generally poor for unmodified peptides — proteolytic enzymes (pepsin, trypsin) and intestinal pH degrade most peptide bonds before systemic absorption.
- Exceptions: Cyclic peptides, peptidomimetics, and nanoparticle-encapsulated formulations show improved oral stability in research models. KPV is a notable example studied for oral gut-targeted delivery.
- Research context: Oral peptide delivery remains an active area of pharmaceutical research; not standard for most current research-grade compounds.
Intravenous Administration
- Bioavailability: 100% by definition — direct systemic delivery.
- Onset: Immediate; used where rapid plasma concentration is required in experimental design.
- Considerations: Requires sterile, endotoxin-free formulations. Short half-life for many peptides necessitates continuous infusion or frequent dosing in study protocols.
Key Formulation Considerations
- pH: Most peptides are stable between pH 4.5–7.0; outside this range, hydrolysis accelerates. Note: IGF peptides require acetic acid solution as primary solvent — see our IGF-1 & Growth Factors overview.
- Excipients: Bacteriostatic agents (e.g. benzyl alcohol in bacteriostatic water) extend reconstituted stability but may affect certain assay systems.
- Concentration: Higher concentrations reduce injection volume but may increase aggregation risk for some peptides.
Summary
- Subcutaneous is the most widely used route for research peptides due to consistent bioavailability and practical administration.
- Intranasal delivery is gaining traction for CNS-targeted peptide research.
- Oral bioavailability remains a significant challenge for unmodified peptides.
- Route selection should be determined by the specific research objective, peptide properties, and study model.
All products supplied by Vanta Labs are intended strictly for laboratory and research purposes.